New obesity drug aims for major weight loss in phase 3 trial
NCT ID NCT06174779
First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time
Summary
This phase 3 study tests an investigational drug called HM11260C for weight loss in adults with obesity who do not have diabetes. Participants must have a body mass index (BMI) of 30 or higher, or a BMI of 27 or higher with related health issues like high blood pressure. The trial compares the drug against a placebo to see how much weight people lose and how many achieve at least a 5% reduction in body weight.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HM11260C
- What this could lead to
- If successful, this could provide a new medication option for significant weight loss in people with obesity.
- What could go wrong
- This is a phase 3 trial, but the drug may still fail to show sufficient benefit or cause side effects. Weight regain after stopping is possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kangbuk samsung hospital
Seoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Timing your meals or halving your rice: a new trial tests simple diet hacks for weight loss and blood sugar control
- Does injection location matter for a new Weight-Loss drug? a trial investigates
- Can a new drug boost Semaglutide's power against diabetes and obesity?
- Can a Normal-Weight baseline improve heart risk assessment in type 1 diabetes?
- A daily pill for obesity? zenagamtide faces its biggest test yet.
- Dance and walking may boost heart health in obesity — a trial puts it to the test